Mesenchymal Stem Cells Global Market Report 2024

The mesenchymal stem cells market size has grown rapidly in recent years. It will grow from $3.0 billion in 2023 to $3.38 billion in 2024 at a compound annual growth rate (CAGR) of 12.5%. The expansion observed during the historical period can be attributed to several factors. These include the paradigm shift towards regenerative medicine, collaborative research endeavors, heightened public awareness of stem cell research, patient advocacy efforts, international collaboration, and initiatives aimed at standardization.

The mesenchymal stem cells market size is expected to see rapid growth in the next few years. It will grow to $5.45 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The projected growth in the forecast period can be attributed to several factors, including ongoing advancements in genetic engineering technologies, the increasing adoption of personalized medicine approaches, the integration of artificial intelligence (AI) and data analytics, advancements in biomaterials science and 3D bioprinting technologies, the development of microfluidic devices and organ-on-a-chip models, as well as the adoption of next-generation manufacturing technologies. Major trends expected during this period include the expansion of bioprinting and tissue engineering, advancements in gene editing technologies, the broadening of clinical applications, the emergence of combination therapies, and the utilization of mesenchymal stem cell-derived extracellular vesicles (EVs).

The mesenchymal stem cells (MSC) market is anticipated to experience growth driven by the increasing awareness surrounding regenerative medicine. Regenerative medicine, an emerging interdisciplinary field, aims to restore impaired cellular, tissue, or organ function caused by various factors such as disease, injury, or aging. This growth is fueled by rising clinical trials, the prevalence of chronic and age-related conditions, and the trend towards personalized medicine. Mesenchymal stem cells (MSCs) hold significant promise in regenerative medicine due to their capacity to differentiate into various cell types, modulate immune responses, and facilitate tissue repair and regeneration across a spectrum of medical conditions. For instance, a report by the Alliance for Regenerative Medicine revealed a substantial increase in therapeutic developers engaged in cells, gene, and tissue-engineering therapies worldwide in Q1 2023 compared to Q1 2022. Additionally, financing for regenerative medicine and advanced therapies has seen a notable uptick, underscoring the growing awareness and investment in this field.

Leading companies in the mesenchymal stem cells (MSCs) market are leveraging innovative technologies, such as GMP-compliant isolation, to enhance their market presence. GMP-compliant isolation involves isolating cells, including MSCs, in accordance with Good Manufacturing Practice regulations to ensure consistent production and quality control. For example, PromoCell recently introduced PromoExQ MSC Growth Medium XF, a serum- and xeno-free medium specifically formulated for the expansion of human MSCs in GMP-regulated environments. This medium adheres to the highest quality standards and is EXCiPACT GMP-certified, facilitating consistent growth and maintenance of MSCs sourced from various origins such as bone marrow, umbilical cord matrix, and adipose tissue.

In July 2021, Brooklyn ImmunoTherapeutics acquired Novellus Therapeutics for $125 million, bolstering its position as a platform company with a pipeline of advanced cellular, gene editing, and cytokine programs. Novellus Therapeutics, a developer of next-generation engineered mesenchymal stem cells, aligns with Brooklyn's vision to advance innovative therapies in the regenerative medicine space.

Major companies operating in the mesenchymal stem cells market are Thermo Fischer Scientific Inc., Danaher Corporation, Merck KgaA, Becton, Dickinson, and Company, Fujifilm Holdings Corporation, Corning Inc., Daiichi Sankyo, Lonza Group, Terumo Corporation, Sartorius AG, Getinge AB, Bio-Rad Laboratories, Eppendorf AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmBH, Takara Bio Group, Organogenesis Holdings Inc., Vericel Corporation, HiMedia Laboratories, PromoCell GmbH, CellGenix GmBH, Anterogen Co. Ltd., Pluristem Therapeutics Inc., American Cryostem Corporation.

North America was the largest region in the mesenchymal stem cells market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mesenchymal stem cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mesenchymal stem cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Mesenchymal stem cells (MSCs) represent a type of multipotent adult stem cells distributed across various tissues in the body, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. These cells possess the capacity to differentiate into diverse cell types, including osteoblasts (bone cells) and chondrocytes (cartilage cells), rendering them valuable in treating various conditions such as bone and cartilage repair, myocardial infarction, and neurological disorders.

The primary types of mesenchymal stem cells are autologous and allogeneic. Autologous pertains to medical procedures where cells, tissues, or substances are obtained from an individual and then reintroduced into the same individual. Various product types are available, including cells and cell lines, kits, media and reagents, among others, along with different workflow types such as cell sourcing and isolation, culture and cryopreservation, differentiation, and characterization. These are utilized for several indications, including bone and cartilage repair, cardiovascular diseases, inflammatory and immunological diseases, liver diseases, cancer, GvHD, among others, and across various applications such as disease modeling, drug development and discovery, stem cell banking, tissue engineering, and toxicology studies.

The mesenchymal stem cells market research report is one of a series of new reports that provides mesenchymal stem cells market statistics, including mesenchymal stem cells industry global market size, regional shares, competitors with a mesenchymal stem cells market share, detailed mesenchymal stem cells market segments, market trends, and opportunities, and any further data you may need to thrive in the mesenchymal stem cells industry. This mesenchymal stem cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mesenchymal stem cells market consists of revenues earned by entities by providing services such as cell isolation and culture techniques, cryopreservation and storage, custom cell development, and MSC-based therapeutics development. The market value includes the value of related goods sold by the service provider or included within the service offering. The mesenchymal stem cells market also includes sales of MSC differentiation inducers, scaffolds and matrices, MSC-derived exosomes, and cryopreservation agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.